Tumor-Associated Immune Cell Profiling for Early Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer detection methods relying on endogenous biomarkers are limited by sensitivity due to rapid biomarker clearance, low concentration, and high background signals, making early cancer diagnosis challenging, especially since many cancers are diagnosed at advanced stages.
Innovation Solution
Measuring cancer traits of tumor-associated immune cells (TAICs) or TAIC-derived biomarkers in fluid samples, comparing these profiles to reference profiles, and using Raman spectroscopy and machine learning algorithms to identify cancer characteristics such as type, stage, and metastatic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If endogenous biomarkers (circulating cell free DNA, circulating tumor cells, exosomes) are used for cancer diagnosis, then non-invasive diagnosis is achieved, but sensitivity is limited due to rapid biomarker clearance rate, low concentration in circulation and high background signals
Solution Approach 1:
The patent introduces tumor-associated immune cells (TAICs) as intermediary biomarkers. These immune cells interact with tumor cells in the tumor microenvironment and carry diagnostic information about cancer presence, type, and stage. TAICs serve as mediators that bridge the gap between tumor pathology and detectable signals in body fluids, overcoming the limitations of direct tumor-derived biomarkers.
Solution Approach 2:
The patent uses immune cell profiles as copies or proxies of tumor characteristics. Instead of directly detecting tumor DNA or cells (which are scarce and degraded), the method profiles immune cells that have interacted with tumors, creating a functional copy of tumor presence and characteristics that can be detected with high sensitivity in circulating fluids.
2Loss of time
If endogenous biomarkers are used for cancer detection, then early detection is attempted, but diagnosis is limited to advanced stages due to low biomarker concentration and high background signals
Solution Approach 1:
Tumor-associated immune cells act as early warning intermediaries. These immune cells are recruited to the tumor microenvironment early in cancer development and remain there throughout disease progression. By profiling these cells, the method can detect cancer at early stages before traditional biomarkers become detectable, as TAICs are present in circulating fluids from the outset of tumor formation.
Solution Approach 2:
The patent changes the detection parameter from direct tumor biomarker concentration (which remains low) to immune cell profile characteristics (which show significant changes). By measuring parameters such as immune cell gene expression, protein markers, and functional characteristics rather than relying on scarce tumor-derived molecules, the method achieves high detection accuracy at early cancer stages.
3Measurement precision
If immune system is focused for cancer detection, then sensitivity is improved through tumor-associated immune cell profiling, but device complexity increases due to multi-parameter measurement requirements
Solution Approach 1:
The patent segments the complex immune cell profiling into distinct measurable components. Instead of requiring complete immune system characterization, the method focuses on specific tumor-associated immune cell subsets (CD4+ T cells, CD8+ T cells, NK cells, macrophages) and their specific markers. This segmentation allows high sensitivity to be achieved through targeted measurement of relevant parameters rather than comprehensive analysis.
Solution Approach 2:
The patent develops a universal profiling approach that can detect multiple cancer characteristics (presence, type, stage) through a single integrated immune cell analysis system. The same multi-parameter measurement platform used to assess immune cell composition also evaluates functional characteristics and tumor stage, making the system multi-functional and reducing overall complexity compared to separate specialized assays for each parameter.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves high sensitivity and specificity in early cancer detection and prognosis, accurately distinguishing between benign and malignant tumors, and predicting metastasis using immune cell profiles.
Implementation Method 1
measuring a value of one or more cancer traits of at least one tumor associated immune cell (TAIC) or TAIC-derived biomarker in a fluid sample obtained from the subject
Data Source
AI summary
Provided is a method of providing a cancer assessment for a subject, comprising (i) measuring a value of one or more cancer traits of at least one tumor associated immune cell (TAIC) or TAIC-derived biomarker in a fluid sample obtained from the subject to obtain a test profile; (ii) comparing the test profile to one or more reference profiles; (iii) wherein similarity or a differential in the test profile to the one or more reference profiles is indicative of one or more cancer characteristics; and (iv) based on the one or more cancer characteristics, providing the cancer assessment of the subject.